Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mepivacaine IANB Success in Symptomatic Irreversible Pulpitis
NCT05238727Unknown
- Sponsor
- Cairo University
- Start
- Mar 2022
- Primary completion
- Mar 2023
- Modality
- Small Molecules
01
Overview
Randomised trial of mepivacaine and articaine in irreversible pulpitis (3 arms), sponsored by Cairo University. Primary endpoint: Anesthetic success. Status: unknown.
02
Drugs
mepivacainearticaine
03
Conditions
irreversible pulpitis
Beyond the preview
Go deeper on NCT05238727.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05238727.